The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2025 | The need to refine the definition of nodal-based lymphomas
Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, comments on the need to refine the definition of nodal-based lymphomas. Dr de Leval hopes that the next consensus process will address this unresolved question to establish more biologically meaningful definitions. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are several, but let’s take an example that’s borrowed to the group of diseases that we most frequently encounter, which are the nodal-based lymphomas. I think there’s still a gray zone between the group of follicular helper T-cell lymphoma and what we call by default, not otherwise specified. The reason being that we have guidelines, we have criteria to define what is a TFH phenotype, but it’s also widely acknowledged that probably our definition is currently insufficient and may capture cases that probably are not biologically related to the group of TFH lymphoma...
There are several, but let’s take an example that’s borrowed to the group of diseases that we most frequently encounter, which are the nodal-based lymphomas. I think there’s still a gray zone between the group of follicular helper T-cell lymphoma and what we call by default, not otherwise specified. The reason being that we have guidelines, we have criteria to define what is a TFH phenotype, but it’s also widely acknowledged that probably our definition is currently insufficient and may capture cases that probably are not biologically related to the group of TFH lymphoma. So we need to come up with where to draw the line and how to best define TFH lymphoma in order to keep up with a group that’s biologically meaningful.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
